| AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | Mus musculus, Homo sapiens, Pimephales promelas, Colinus virginianus, Rattus norvegicus | 0.12 | KE:864 | Decreased, Body Weight |
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.25 | KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory |
| AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Monkey sp., Rat | 0.1 | KE:341 | Impairment, Learning and memory |
| AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental disorder of mental health | WPHA/WNT Endorsed | Rat, Mouse, Human | 0.1 | KE:341 | Impairment, Learning and memory |
| AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Gallus gallus | 0.4 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality |
| AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary system disease | WPHA/WNT Endorsed | Mouse, Human | 0.2 | KE:827 | sensitisation, skin |
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.12 | KE:402 | Cognitive function, decreased |
| AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | Mouse, Zebrafish, Rats, Human | 0.2 | KE:1001 | Increased, Developmental Defects |
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.22 | KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory |
| AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental disorder of mental health | WPHA/WNT Endorsed | Homo sapiens, Rattus sp. | 0.1 | KE:341 | Impairment, Learning and memory |
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.17 | KE:330 | Decrease, Fertility |
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.11 | KE:402 | Cognitive function, decreased |
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.5 | KE:885 | Increase, Cancer |
| KE:155 | Inadequate DNA repair |
| AOP:148 | EGFR Activation Leading to Decreased Lung Function | Respiratory system disease | Under Development | Human, Mouse, Rat | 0.25 | KE:1250 | Decrease, Lung function |
| AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular system disease | Under Development | Human, Mouse, Rat, Cow | 0.2 | KE:952 | Hypertension |
| KE:937 | KE7 : Impaired, Vasodilation |
| AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | Chicken, Zebrafish, Mouse, Rattus norvegicus | 0.29 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality |
| AOP:203 | 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline | Reproductive system disease | - | | 0.12 | KE:1141 | Decreased, Reproductive Success |
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.33 | KE:1263 | Necrosis |
| KE:1262 | Apoptosis |
| AOP:237 | Substance interaction with lung resident cell membrane components leading to atherosclerosis | Cardiovascular system disease | Under Development | Human, Mouse | 0.2 | KE:1443 | Atherosclerosis |
| AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | Lemna minor, Lemna gibba | 0.09 | KE:1521 | Decrease, Growth |
| AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous system disease | - | Human | 0.14 | KE:1514 | Neurodegeneration |
| AOP:261 | L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility | Cardiovascular system disease | Under Development | Vertebrates | 0.12 | KE:1535 | Heart failure |
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | | 0.17 | KE:10013 | Impaired growth and development |
| AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.29 | KE:155 | Inadequate DNA repair |
| KE:1556 | Increase, lung cancer |
| AOP:278 | IKK complex inhibition leading to liver injury | Unclassified | - | | 0.12 | KE:1549 | Liver Injury |
| AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous system disease | - | | 0.1 | KE:352 | N/A, Neurodegeneration |
| AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.25 | KE:1521 | Decrease, Growth |
| AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.25 | KE:1521 | Decrease, Growth |
| AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | Daphnia magna | 0.25 | KE:1521 | Decrease, Growth |
| AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | Daphnia magna | 0.25 | KE:1521 | Decrease, Growth |
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:302 | Lung surfactant function inhibition leading to decreased lung function | Respiratory system disease | Under Development | Human, Mouse, Rat | 0.2 | KE:1250 | Decrease, Lung function |
| AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | Mammals | 0.14 | KE:1670 | Lung cancer |
| AOP:304 | TBX1 inhibition leading to congenital cardiac conotruncal anomalies | Cardiovascular system disease | - | | 0.17 | KE:1685 | Anomalies, Congenital cardiac conotruncal |
| AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | Fish | 0.25 | KE:1521 | Decrease, Growth |
| AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1521 | Decrease, Growth |
| AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1521 | Decrease, Growth |
| AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | Daphnia magna, Daphnia middendorffiana, Daphnia pulex, Daphnia pulicaria, Daphnia parvula | 0.17 | KE:1521 | Decrease, Growth |
| AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | | 0.2 | KE:1521 | Decrease, Growth |
| AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | | 0.4 | KE:1521 | Decrease, Growth |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation |
| AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular system disease | Under Development | Homo sapiens | 0.29 | KE:1846 | Thrombosis and Disseminated Intravascular Coagulation |
| KE:1869 | Diminished protective oxidative stress response |
| AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary system disease | - | | 0.17 | KE:1603 | Chronic kidney disease |
| AOP:394 | SARS-CoV-2 infection of olfactory epithelium leading to impaired olfactory function (short-term anosmia) | Endocrine system disease | Under Development | | 0.14 | KE:1873 | impaired olfactory function (anosmia) |
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory system disease | - | Homo sapiens | 0.25 | KE:1250 | Decrease, Lung function |
| AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | | 0.17 | KE:1670 | Lung cancer |
| AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | | 0.2 | KE:1670 | Lung cancer |
| AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory system disease | - | | 0.2 | KE:1250 | Decrease, Lung function |
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | | 0.5 | KE:1250 | Decrease, Lung function |
| KE:1262 | Apoptosis |
| AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | | 0.25 | KE:1670 | Lung cancer |
| AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory system disease | - | Human | 0.17 | KE:1250 | Decrease, Lung function |
| AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory system disease | - | Human | 0.17 | KE:1250 | Decrease, Lung function |
| AOP:430 | Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation | Viral infectious disease | Under Development | Mink, Ferret, Cat, Dog, Syrian golden hamster, Rhesus macaque, Lowland gorilla, Crab eating macaque, African green monkeys, Humans, Hippopotamus amphibius, Bank vole, Lynx canadensis, Puma concolor, Panthera tigris jacksoni, Panthera uncia, Prionailurus viverrinus, Crocuta crocuta, Arctictis binturong, Odocoileus virginianus, American mink, Nasua nasua, Panthera leo, Sus scrofa, European rabbit, Castor fiber, Aonyx cinereus, Vulpes vulpes, Nyctereutes procyonoides, Tupaia belangeri, Bos taurus, Odocoileus hemionus, Peromyscus maniculatus bairdii, Cynopterus brachyotis, Common marmoset, Baboon | 0.2 | KE:1939 | Viral infection and host-to-host transmission, proliferated |
| AOP:433 | hERG channel blockade leading to sudden cardiac death | Cardiovascular system disease | - | Human | 0.17 | KE:1964 | Sudden cardiac death |
| AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular system disease | - | | 0.17 | KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population |
| KE:1919 | Increased, Cardiac Dysregulation |
| AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive disorder | Under Review | Rattus norvegicus, Mouse, Humans | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary system disease | - | | 0.17 | KE:1097 | Occurrence, renal proximal tubular necrosis |
| KE:759 | Increased, Kidney Failure |
| AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | | 0.24 | KE:2001 | Cardiac hypertrophy |
| KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population |
| KE:1198 | Activation, Macrophages |
| KE:1443 | Atherosclerosis |
| AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | Human | 0.11 | KE:1670 | Lung cancer |
| AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal system disease | Under Review | Zebrafish, Mouse, Human, Sebastiscus marmoratus, Salmo salar, Chicken | 0.17 | KE:947 | Increase, Early Life Stage Mortality |
| AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | Zebrafish, Mouse, Human, Chicken | 0.33 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality |
| AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Mouse, Monkey, Human | 0.12 | KE:402 | Cognitive function, decreased |
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.11 | KE:402 | Cognitive function, decreased |
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | | 0.27 | KE:2034 | liver dysfunction |
| KE:149 | Increase, Inflammation |
| KE:1262 | Apoptosis |
| AOP:472 | DNA adduct formation leading to kidney failure | Urinary system disease | - | | 0.33 | KE:1097 | Occurrence, renal proximal tubular necrosis |
| KE:759 | Increased, Kidney Failure |
| KE:149 | Increase, Inflammation |
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental disorder of mental health | Under Development | Mouse, Rat, Human, Caenorhabditis elegans | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular system disease; Thoracic disease | Under Development | | 0.14 | KE:2215 | Decrease Left Ventricular function |
| AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular system disease; Thoracic disease | Under Development | | 0.2 | KE:2215 | Decrease Left Ventricular function |
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.29 | KE:1869 | Diminished protective oxidative stress response |
| KE:402 | Cognitive function, decreased |
| AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental disorder of mental health | - | | 0.09 | KE:341 | Impairment, Learning and memory |
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:2150 | Neurological disorder |
| KE:191 | Neuronal dysfunction |
| AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.25 | KE:341 | Impairment, Learning and memory |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.43 | KE:1262 | Apoptosis |
| KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory |
| AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.25 | KE:2150 | Neurological disorder |
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.4 | KE:885 | Increase, Cancer |
| KE:149 | Increase, Inflammation |
| AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.17 | KE:2161 | Increase, Vascular disrupting effects |
| AOP:508 | Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.14 | KE:2161 | Increase, Vascular disrupting effects |
| AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular system disease | - | | 0.14 | KE:2161 | Increase, Vascular disrupting effects |
| AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.1 | KE:2161 | Increase, Vascular disrupting effects |
| AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.06 | KE:2161 | Increase, Vascular disrupting effects |
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.2 | KE:885 | Increase, Cancer |
| AOP:519 | Cardiac ion channels blockade leading to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | Human and other cells in culture, Guinea pig, Rabbit | 0.25 | KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population |
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.2 | KE:341 | Impairment, Learning and memory |
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | | 0.08 | KE:341 | Impairment, Learning and memory |
| AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | | 0.17 | KE:341 | Impairment, Learning and memory |
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.33 | KE:885 | Increase, Cancer |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation |
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.22 | KE:1262 | Apoptosis |
| KE:341 | Impairment, Learning and memory |
| AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular system disease | - | Fish | 0.29 | KE:2261 | Decreased, blood plasma volume |
| KE:1535 | Heart failure |
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular system disease | - | Human, Mouse, Rat | 0.2 | KE:1535 | Heart failure |
| AOP:551 | Increased Muscarinic M2 Receptor leading to Arrhythmia | Symptom | - | Human, Mouse, Rat | 0.4 | KE:1098 | Increased, blood potassium concentration |
| KE:1106 | Occurrence, cardiac arrhythmia |
| AOP:552 | Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP) | Cardiovascular system disease | - | Human, Rat, Mouse | 0.17 | KE:1535 | Heart failure |
| AOP:553 | Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure | Cardiovascular system disease | - | Human, Rodents, Dogs, Pigs, Insects, Fish | 0.25 | KE:1535 | Heart failure |
| AOP:554 | β-adrenergic receptor agonists leading to arrhythmias. | Symptom | - | Human and other cells in culture, Rodents, Macaca mulatta, Zebrafish, Gallus gallus | 0.25 | KE:1106 | Occurrence, cardiac arrhythmia |
| AOP:555 | Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Dogs, Rat, Guinea pig, Rabbits, Zebrafish | 0.2 | KE:1535 | Heart failure |
| AOP:556 | Decreased Na/K ATPase activity leading to heart failure | Cardiovascular system disease | - | | 0.17 | KE:1535 | Heart failure |
| AOP:558 | Phosphodiesterase inhibition leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Rodents, Dog, Pig, Zebrafish | 0.17 | KE:1535 | Heart failure |
| AOP:559 | Inhibition of acetylcholinesterase (AChE) leading to arrhythmias | Symptom | - | Human and other cells in culture, Rattus norvegicus, Dogs, Sus scrofa, Zebrafish, Insecta sp. BOLD:AAN5199 | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
| AOP:560 | Inhibition of Funny current (If) leading to Arrhythmias | Symptom | - | Human and other cells in culture, Rodents, Dogs, Zebrafish | 0.25 | KE:1106 | Occurrence, cardiac arrhythmia |
| AOP:562 | HCN Channel Inhibition leading to Arrhythmias | Symptom | - | Human and other cells in culture, Dogs, Zebrafish, Rodents, Pigs | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |